26May 2024
CAPOX Regimen Proves Effective for Advanced Ampulla of Vater Carcinoma

CAPOX Regimen Proves Effective for Advanced Ampulla of Vater Carcinoma

The study investigated the efficacy and safety of the capecitabine and oxaliplatin (CAPOX) regimen in patients with advanced adenocarcinoma of the ampulla of Vater (AoV). The study included 42 patients, with 14 receiving CAPOX as first-line and 28 as second-line therapy. At a median follow-up of 9 months, the median progression-free survival was 4.38 months, and the median overall survival was 9.57 months. The objective response and disease control rates were 38.1% and 61.9%, respectively. Patients receiving CAPOX as second-line treatment had poorer outcomes compared to first-line. The study confirmed the therapeutic efficacy and safety of CAPOX in a real-world setting, highlighting the need for further research to determine its optimal use in the palliative management of advanced AoV carcinoma.

  • #oncology

Like

Save

Share